ライフサイエンスコーパス: irritable bowel syndrome

1 scribed (e.g. inflammatory bowel disease and irritable bowel syndrome).

2 findings, are nonspecific, and can simulate irritable bowel syndrome.

3 es such as fibromyalgia, chronic fatigue and irritable bowel syndrome.

4 cupuncture is a cost-effective treatment for irritable bowel syndrome.

5 osed inflammatory bowel disease and 877 with irritable bowel syndrome.

6 be cost-effective for those with more severe irritable bowel syndrome.

7 other involving children suffering from the irritable bowel syndrome.

8 tion between infection with Blastocystis and irritable bowel syndrome.

9 rted polymorphisms in the pathophysiology of irritable bowel syndrome.

10 e clearly established a genetic component in irritable bowel syndrome.

11 abdominal pain and cramping in patients with irritable bowel syndrome.

12 tem, such as chemotherapy-induced emesis and irritable bowel syndrome.

13 ntirely functional, such as in some cases of irritable bowel syndrome.

14 s may have a role in nondiarrhea predominant irritable bowel syndrome.

15 - have developing roles in the treatment of irritable bowel syndrome.

16 overgrowth may be important for treatment of irritable bowel syndrome.

17 in is effective in preventing postinfectious irritable bowel syndrome.

18 ntary and alternative medicine therapies for irritable bowel syndrome.

19 eral hypersensitivity is a characteristic of irritable bowel syndrome.

20 possible therapies for certain patients with irritable bowel syndrome.

21 h mucosa and blood have been demonstrated in irritable bowel syndrome.

22 ses substantial morbidity and postinfectious irritable bowel syndrome.

23 Patients often have a previous diagnosis of irritable bowel syndrome.

24 ations in sensory processing associated with irritable bowel syndrome.

25 disorder, multiple chemical sensitivity, and irritable bowel syndrome.

26 s in responsiveness to nondrug therapies for irritable bowel syndrome.

27 der-related differences in the prevalence of irritable bowel syndrome.

28 ultimately provide a cure for patients with irritable bowel syndrome.

29 NR1) have been associated with some forms of irritable bowel syndrome.

30 ergrowth participates in the pathogenesis of irritable bowel syndrome.

31 hanced toxin sensitivity in a mouse model of irritable bowel syndrome.

32 psy, ataxia, pain, arrhythmia, myotonia, and irritable bowel syndrome.

33 The prevalences of irritable bowel syndrome (39.4%) by Rome III criteria an

34 ), 6.78% in Crohn's disease (4/59), 5.82% in irritable bowel syndrome (51/877), and 4.9% in the remai

35 valences (per 100 residents) were stable for irritable bowel syndrome (8.3% and 11.4%, respectively)

36 Of them, 305 (16.5%) had AP-FGD [irritable bowel syndrome = 91(4.9%), functional dyspepsi

37 e into the development of new approaches for irritable bowel syndrome, a multifactorial disorder for

38 who are in remission and those who developed irritable bowel syndrome after enteric infection continu

39 in the treatment of constipation-predominant irritable bowel syndrome and chronic constipation.

40 ate the persistence, prevalence, and risk of irritable bowel syndrome and chronic fatigue 6 years aft

41 ing is associated with an increased risk for irritable bowel syndrome and chronic fatigue 6 years lat

42 Clinical studies show that patients with irritable bowel syndrome and colonic diseases frequently

43 Although symptomatic irritable bowel syndrome and Crohn's disease patients ha

44 nd pharmacological trials of novel agents in irritable bowel syndrome and diabetic dyspepsia.

45 nic gastrointestinal diseases-liver disease, irritable bowel syndrome and dyspepsia, and inflammatory

46 associated with diarrheal conditions such as irritable bowel syndrome and enteric infections.

47 gastrointestinal tract disorders, including irritable bowel syndrome and gastroesophageal reflux dis

48 with postinfectious complications, including irritable bowel syndrome and Guillain-Barre syndrome.

49 ter, are at increased risk of postinfectious irritable bowel syndrome and inflammatory bowel disease

50 Colon disorders, including irritable bowel syndrome and inflammatory bowel disease,

51 sit and gut microbial communities, including irritable bowel syndrome and inflammatory bowel disease.

52 long-term effects, including postinfectious irritable bowel syndrome and inflammatory bowel disease.

53 ensal gut flora in such common conditions as irritable bowel syndrome and inflammatory bowel disease.

54 Both irritable bowel syndrome and inflammatory bowel diseases

55 , appeared to be most genetically similar to irritable bowel syndrome and most environmentally simila

56 stion that SIBO may be a causative factor in irritable bowel syndrome and of its constituent symptoms

57 successfully treat constipation-predominant irritable bowel syndrome and recent studies show that ex

58 (EPI) confound interpretation of findings in irritable bowel syndrome and severe renal insufficiency.

59 developing after infection (post-infectious irritable bowel syndrome) and this has proved a profitab

60 ysiology, etiology, pathogenesis, diagnosis, irritable bowel syndrome, and IBS.

61 broid food poisoning, histamine intolerance, irritable bowel syndrome, and inflammatory bowel disease

62 These include inflammatory bowel diseases, irritable bowel syndrome, and metabolic (i.e. obesity, n

63 robiota, such as inflammatory bowel disease, irritable bowel syndrome, and metabolic syndrome, to nam

64 owel diseases, celiac disease, food allergy, irritable bowel syndrome, and--more recently recognized-

65 festations of celiac disease that include an irritable bowel syndrome, anemia, osteoporosis, neurolog

66 ders, such as inflammatory bowel disease and irritable bowel syndrome, are associated with exaggerate

67 disorders (cardiovascular disease, diabetes, irritable bowel syndrome, asthma, and others).

68 to human physiology and to diseases such as irritable bowel syndrome, autism, anxiety, depression, a

69 subjects (aged 24-61 y, 6 men) with NCGS and irritable bowel syndrome (based on Rome III criteria), b

70 al gastrointestinal disorders, most commonly irritable bowel syndrome but also other functional and o

71 nalities with inflammatory bowel disease and irritable bowel syndrome but were focused on associative

72 EC has been implicated in the development of irritable bowel syndrome, but this remains to be confirm

73 ota of patients with constipated-predominant irritable bowel syndrome (C-IBS) displays chronic dysbio

74 ely prescribing antibiotics to patients with irritable bowel syndrome can be endorsed.

75 This activation may have relevance to irritable bowel syndrome characterized by lower pain thr

76 terpersonal therapy, and antidepressants for irritable bowel syndrome, chronic fatigue syndrome, and

77 , management, and role in conditions such as irritable bowel syndrome, chronic fatigue, and autoimmun

78 Chronic pain syndromes irritable bowel syndrome, chronic pelvic pain, and fibro

79 y, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in

80 searched by using medical subject headings ("irritable bowel syndrome;" "colonic diseases, functional

81 in small intestinal bacterial overgrowth in irritable bowel syndrome continues, the utility and spec

82 While interest in bacterial overgrowth in irritable bowel syndrome continues, the utility and spec

83 rome, reactive arthritis, and postinfectious irritable bowel syndrome) contribute considerably to the

84 ur findings link duplications in TPSAB1 with irritable bowel syndrome, cutaneous complaints, connecti

85 symptoms in women with diarrhea-predominant irritable bowel syndrome (D-IBS).

86 In the exposed group, the prevalence of irritable bowel syndrome decreased by 6.7% (RR, 0.85 [95

87 The peripheral component is prominent in irritable bowel syndrome developing after infection (pos

88 ease in IBD risk for persons with a previous irritable bowel syndrome diagnosis.

89 opsies were also taken from 16 patients with irritable bowel syndrome diarrhea who comprised the cont

90 est drug to be approved for the treatment of irritable bowel syndrome-diarrhoea is rifaximin, which w

91 expanded from 1946 to December 2014 for IBS, irritable bowel syndrome, diet, treatment, and therapy.

92 tic syndromes', 'Chronic fatigue syndrome', 'Irritable bowel syndrome', 'Fibromyalgia', 'Dopamine and

93 ted with chronic prostatitis/CPPS, including irritable bowel syndrome, fibromyalgia, and chronic fati

94 r directly co-morbid somatic disorders, e.g. irritable bowel syndrome, fibromyalgia, or migraine.

95 This issue provides a clinical overview of irritable bowel syndrome, focusing on diagnosis, treatme

96 d in the setting of differentiating IBD from irritable bowel syndrome, for grading inflammation, to d

97 nter placebo-controlled trial, children with irritable bowel syndrome, functional abdominal pain, or

98 female patients with moderate to severe FBD (irritable bowel syndrome, functional abdominal pain, pai

99 mechanisms may predispose the individual to irritable bowel syndrome, gastroesophageal reflux diseas

100 (FC), Gastrointestinal Symptoms Rating Scale-Irritable Bowel Syndrome (GSRS-IBS) and Hospital Anxiety

101 he Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) into German and to e

102 red by Gastrointestinal Symptom Rating Scale Irritable Bowel Syndrome (GSRS-IBS) version.

103 antibiotics and concurrently, postinfectious irritable bowel syndrome has been associated with a long

104 Traditionally, irritable bowel syndrome has been considered to be a dis

105 Irritable bowel syndrome has been referred to as a funct

106 The study of post-infectious irritable bowel syndrome has revealed the importance of

107 treatment options for diarrhoea-predominant irritable bowel syndrome have had not very promising res

108 also collected from 151 patients with CD or irritable bowel syndrome (IBS) (controls).

109 ed by the intestinal mucosa of patients with irritable bowel syndrome (IBS) affect the function of en

110 Irritable bowel syndrome (IBS) affects 7% to 21% of the

111 tudies have shown an increased prevalence of irritable bowel syndrome (IBS) after acute gastroenterit

112 patients (63.8%) had a previous diagnosis of irritable bowel syndrome (IBS) and 23 (28.8%) had one of

113 es from patients of colorectal cancer (CRC), irritable bowel syndrome (IBS) and controls to be run th

114 We investigated the role of TRPV1 in irritable bowel syndrome (IBS) and evaluated if an antag

115 symptoms, which occasionally mimic those of Irritable Bowel Syndrome (IBS) and Fibromyalgia Syndrome

116 hypnotherapy (HT) is effective in pediatric irritable bowel syndrome (IBS) and functional abdominal

117 tious gastroenteritis increases the risk for irritable bowel syndrome (IBS) and functional dyspepsia

118 ists are effective in treating patients with irritable bowel syndrome (IBS) and have anxiolytic effec

119 Irritable bowel syndrome (IBS) and inflammatory bowel di

120 Abuse history is common in irritable bowel syndrome (IBS) and is associated with gr

121 Very few studies report on the prevalence of irritable bowel syndrome (IBS) and its correlates in the

122 Women have a higher prevalence of irritable bowel syndrome (IBS) and possible differences

123 nning to shape a pathophysiological model of irritable bowel syndrome (IBS) and related functional ga

124 creased 5-HT release occurs in patients with irritable bowel syndrome (IBS) and their peak plasma 5-H

125 cally divergent, ulcerative colitis (UC) and irritable bowel syndrome (IBS) are both associated with

126 isease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common functional gas

127 healthy children and pediatric patients with irritable bowel syndrome (IBS) are not well defined.

128 Approximately 1 in ten patients with irritable bowel syndrome (IBS) believe their IBS began w

129 cture is used by patients as a treatment for irritable bowel syndrome (IBS) but the evidence on effec

130 pathophysiology, diagnosis, and treatment of irritable bowel syndrome (IBS) convened to audit the cur

131 elationship between giardiasis diagnosis and irritable bowel syndrome (IBS) diagnosis.

132 suggestive of functional dyspepsia (FD) and irritable bowel syndrome (IBS) frequently overlap with t

133 unctional gastrointestinal disorders such as irritable bowel syndrome (IBS) has shifted fundamentally

134 Patients with irritable bowel syndrome (IBS) have high surgical rates.

135 Only a fraction of patients with irritable bowel syndrome (IBS) have increased perceptual

136 Patients with irritable bowel syndrome (IBS) have increased postprandi

137 odify pain end points in clinical trials for irritable bowel syndrome (IBS) highlights the knowledge

138 care consumption for patients diagnosed with Irritable Bowel Syndrome (IBS) in primary and secondary

139 Irritable bowel syndrome (IBS) is a chronic functional g

140 Irritable Bowel Syndrome (IBS) is a chronic/common condi

141 Irritable Bowel Syndrome (IBS) is a common condition cha

142 Irritable bowel syndrome (IBS) is a common functional ga

143 Irritable bowel syndrome (IBS) is a common gastrointesti

144 Irritable bowel syndrome (IBS) is a common gastrointesti

145 Irritable Bowel Syndrome (IBS) is a functional somatic s

146 Irritable bowel syndrome (IBS) is a gut-brain disorder i

147 Irritable bowel syndrome (IBS) is among the most common

148 BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is associated with intest

149 Irritable bowel syndrome (IBS) is characterized by alter

150 Irritable bowel syndrome (IBS) is more common in patient

151 Irritable bowel syndrome (IBS) is one of the most common

152 Irritable bowel syndrome (IBS) is subtyped as IBS with d

153 f psychosocial disturbances with more severe irritable bowel syndrome (IBS) is well recognized.

154 Patients with irritable bowel syndrome (IBS) often relate symptoms to

155 Patients with Irritable Bowel Syndrome (IBS) often relate their sympto

156 role of the microbiota in the development of irritable bowel syndrome (IBS) only recently has been co

157 ) signaling pathways have been implicated in irritable bowel syndrome (IBS) pathophysiology.

158 lay a role in central pain amplification and irritable bowel syndrome (IBS) pathophysiology.

159 Forty-nine nonconstipated irritable bowel syndrome (IBS) patients (26 female) rece

160 HPA axis response to a visceral stressor in irritable bowel syndrome (IBS) patients and healthy cont

161 efore aversive pelvic visceral distention in irritable bowel syndrome (IBS) patients and their possib

162 Visceral hypersensitivity in irritable bowel syndrome (IBS) patients has been documen

163 Syndrome (FMS) is a frequent comorbidity in Irritable Bowel Syndrome (IBS) patients with a higher fu

164 This study investigated Irritable Bowel Syndrome (IBS) prevalence in a sample of

165 The diagnosis of irritable bowel syndrome (IBS) relies on symptom-based c

166 Irritable bowel syndrome (IBS) remains an incompletely u

167 The pathophysiology of irritable bowel syndrome (IBS) remains enigmatic; abnorm

168 ll but significant subgroup of patients with irritable bowel syndrome (IBS) report a sudden onset of

169 Patients with irritable bowel syndrome (IBS) seen by a gastroenterolog

170 sorbed fermentable carbohydrates can provoke irritable bowel syndrome (IBS) symptoms by escaping abso

171 acy of psychological treatments for reducing irritable bowel syndrome (IBS) symptoms, the mechanisms

172 suspected food intolerances in patients with irritable bowel syndrome (IBS) using confocal laser endo

173 entable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms.

174 entable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms.

175 ept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C)

176 st, which has been approved for treatment of irritable bowel syndrome (IBS) with constipation in wome

177 ciated with colonic transit in patients with irritable bowel syndrome (IBS) with diarrhea.

178 treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea.

179 showed the benefit of a 5HT(3) antagonist in irritable bowel syndrome (IBS) with diarrhoea (IBS-D) an

180 of PI sequelae among exposed was as follows: irritable bowel syndrome (IBS), 3.0; dyspepsia, 1.8; con

181 and male healthy subjects and patients with irritable bowel syndrome (IBS), a common chronic abdomin

182 ve been implicated in the pathophysiology of irritable bowel syndrome (IBS), a visceral pain syndrome

183 the most bothersome symptom by patients with irritable bowel syndrome (IBS), and actual distention ma

184 including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation

185 s are abnormal in the ileum of patients with irritable bowel syndrome (IBS), and whether any abnormal

186 d genetic factors contribute to variation in irritable bowel syndrome (IBS), anxiety and depression.

187 ND & AIMS: Probiotics can reduce symptoms of irritable bowel syndrome (IBS), but little is known abou

188 ssants are effective in patients with severe irritable bowel syndrome (IBS), but the cost-effectivene

189 f these genetic variations with subgroups of irritable bowel syndrome (IBS), functional abdominal pai

190 Irritable bowel syndrome (IBS), functional bloating, fun

191 iated with three other functional disorders; irritable bowel syndrome (IBS), functional dyspepsia (FD

192 the area of functional GI syndromes such as irritable bowel syndrome (IBS), functional dyspepsia, an

193 ose was to evaluate the overlap frequency of irritable bowel syndrome (IBS), gastroesophageal reflux

194 In patients with irritable bowel syndrome (IBS), pain amplification and h

195 Irritable bowel syndrome (IBS), which affects 11% to 14%

196 In irritable bowel syndrome (IBS), which is the most common

197 l gastrointestinal symptoms in patients with irritable bowel syndrome (IBS), yet there is limited evi

198 testinal microbiota and clinical features of irritable bowel syndrome (IBS).

199 pulation each year, and is a risk factor for irritable bowel syndrome (IBS).

200 have important roles in the pathogenesis of irritable bowel syndrome (IBS).

201 the pathophysiology of anxiety disorders and irritable bowel syndrome (IBS).

202 studies of existing diagnostic criteria for irritable bowel syndrome (IBS).

203 microbiota might also play a similar role in irritable bowel syndrome (IBS).

204 relieve symptoms for patients suffering from irritable bowel syndrome (IBS).

205 versus usual care alone for the treatment of Irritable Bowel Syndrome (IBS).

206 important role in the pathophysiology of the irritable bowel syndrome (IBS).

207 used to treat patients with nonconstipating irritable bowel syndrome (IBS).

208 the progression and evaluate the severity of irritable bowel syndrome (IBS).

209 l nervous system is altered in patients with irritable bowel syndrome (IBS).

210 measure patient-reported outcomes (PROs) in irritable bowel syndrome (IBS).

211 he development of drugs for the treatment of irritable bowel syndrome (IBS).

212 nities to develop new therapeutic agents for irritable bowel syndrome (IBS).

213 Visceral hypersensitivity is one feature of irritable bowel syndrome (IBS).

214 y be important in the pathophysiology of the irritable bowel syndrome (IBS).

215 n of 5-HT is involved in the pathogenesis of irritable bowel syndrome (IBS).

216 er-related differences in FGID, particularly irritable bowel syndrome (IBS).

217 ted to reduce symptoms in some patients with irritable bowel syndrome (IBS).

218 ociated with abdominal pain in patients with irritable bowel syndrome (IBS).

219 testinal microbiota and clinical features of irritable bowel syndrome (IBS).

220 sing diet in the management of patients with irritable bowel syndrome (IBS).

221 effective in the treatment of patients with irritable bowel syndrome (IBS).

222 agonists might be involved in development of irritable bowel syndrome (IBS).

223 by mutations in SCN5A also have symptoms of irritable bowel syndrome (IBS).

224 in, constipation, and bloating; diagnoses of irritable bowel syndrome (IBS); and tegaserod prescripti

225 alence of celiac disease among patients with irritable bowel syndrome (IBS); few data are available w

226 fies the FBDs into five distinct categories: irritable bowel syndrome (IBS); functional constipation

227 and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism

228 red an important pathophysiologic symptom in irritable bowel syndrome (IBS); previous gastrointestina

229 of female patients with diarrhea-predominant irritable bowel syndrome (IBS); yet, the mechanism(s) un

230 compared to a milk product in subjects with irritable bowel syndrome (IBS, n = 28).

231 in the treatment of constipation predominant irritable bowel syndrome (IBS-C), a highly prevalent dis

232 ogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C).

233 Patients with diarrhea-predominant irritable bowel syndrome (IBS-D) could benefit from a gl

234 Some patients with diarrhea-predominant irritable bowel syndrome (IBS-D) may have undiagnosed ce

235 ned diarrhea, including diarrhea-predominant irritable bowel syndrome (IBS-D).

236 efficacy and safety for diarrhea-predominant irritable bowel syndrome (IBS-D).

237 valuate the effectiveness of acupuncture for irritable bowel syndrome in primary care when provided a

238 ment of the diarrhea-predominant form of the irritable bowel syndrome in women suggests the importanc

239 Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most n

240 It has suggested novel approaches to irritable bowel syndrome including studies of serotonin

241 orders including inflammatory bowel disease, irritable bowel syndrome, infectious and antibiotic-asso

242 ith active UC, inactive UC, Crohn's disease, irritable bowel syndrome, infectious colitis, and micros

243 ute pancreatitis, bacterial gastroenteritis, irritable bowel syndrome, inflammatory bowel disease, he

244 nfection, small bowel intestinal overgrowth, irritable bowel syndrome, inflammatory bowel disease, po

245 , including Clostridium difficile infection, irritable bowel syndrome, inflammatory bowel diseases, i

246 Irritable bowel syndrome, interstitial cystitis, and oth

247 and of patients with the common symptoms of irritable bowel syndrome, iron deficiency anemia, unexpl

248 w we challenge the widely accepted view that irritable bowel syndrome is an unexplained brain-gut dis

249 Irritable bowel syndrome is characterized by altered sen

250 ecent studies have overthrown the dogma that irritable bowel syndrome is characterized by no abnormal

251 Irritable bowel syndrome is classified as a functional g

252 toms and the strong overlap between GERD and irritable bowel syndrome is due to the influence of NERD

253 noxious stimulation in the context of human irritable bowel syndrome is questionable.

254 In women with constipation-predominant irritable bowel syndrome, linaclotide 1000 microg once d

255 ouse model that reproduces major features of irritable bowel syndrome (long-lasting colon hypersensit

256 interventions are enjoying a renaissance in irritable bowel syndrome management.

257 Postinfectious irritable bowel syndrome may occur in 3% to 17% of patie

258 fibromyalgia, generalized anxiety disorder, irritable bowel syndrome, migraine, obsessive-compulsive

259 hat patients with symptoms of nonconstipated irritable bowel syndrome (NC-IBS) undergo testing for ce

260 hea and colitis, inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, and

261 orphic nature of some pelvic diseases, e.g., irritable bowel syndrome or cystitis.

262 04-1.1), diarrhea (OR, 53; 95% CI, 6.1-471), irritable bowel syndrome (OR, 4.8; 95% CI, 1.6-14), chol

263 ed to control (P<.001) and disease controls (irritable bowel syndrome; P<.001; rheumatoid arthritis;

264 vergrowth is one of the causes suggested for irritable bowel syndrome, particularly for the diarrhoea

265 Irritable bowel syndrome patients form a heterogeneous g

266 een the control group and Crohn's disease or irritable bowel syndrome patients in terms Blastocystis

267 ersensitivity of primary afferent neurons in irritable bowel syndrome patients.

268 Post-infectious irritable bowel syndrome (PI-IBS) is a common gastrointe

269 he role of gut microbiota in post-infectious irritable bowel syndrome (PI-IBS) is convincing.

270 Acupuncture for irritable bowel syndrome provided an additional benefit

271 Irritable bowel syndrome refers to abdominal discomfort

272 Irritable bowel syndrome remains an incompletely underst

273 The role of bacterial overgrowth in irritable bowel syndrome requires further study.

274 ith increased rate ratios (RRs) for incident irritable bowel syndrome (RR, 6.1; 95% confidence interv

275 mens from patients with UC, Crohn's disease, irritable bowel syndrome, sporadic colorectal cancer, or

276 Identical irritable bowel syndrome symptoms are probably due to di

277 ortance of low-grade inflammation in causing irritable bowel syndrome symptoms.

278 toms of functional pain disorders, including irritable bowel syndrome, than men.

279 ents meeting current diagnostic criteria for irritable bowel syndrome, therapeutic approaches shown t

280 o an online database called Transcriptome of Irritable Bowel Syndrome (TIBS).

281 Noninflammatory irritable bowel syndrome was induced by intracolonic ins

282 The term "irritable bowel syndrome" was used to search Clinical Ev

283 chronic fatigue syndrome' and 'Dopamine and irritable bowel syndrome' was carried out until April 20

284 233 patients with irritable bowel syndrome were randomly allocated to eith

285 liaison psychiatric setting in patients with irritable bowel syndrome, where positive benefits have b

286 n important clinical feature associated with irritable bowel syndrome which in some patients has been

287 Irritable bowel syndrome, which affects 5-10% of the pop

288 ion, 15 with functional bloating, and 3 with irritable bowel syndrome with alternating bowel habits)

289 Irritable bowel syndrome with constipation (IBS-C) affec

290 Patients with irritable bowel syndrome with constipation (IBS-C) and p

291 GC-C) that reduces symptoms associated with irritable bowel syndrome with constipation (IBS-C).

292 C) includes functional constipation (FC) and irritable bowel syndrome with constipation (IBS-C).

293 ith functional intestinal disorders (27 with irritable bowel syndrome with constipation, 15 with func

294 ed by >2 symptoms of chronic constipation or irritable bowel syndrome with constipation, and with >2

295 tion subtypes of functional constipation and irritable bowel syndrome with constipation.

296 Some patients with irritable bowel syndrome with diarrhea (IBS-D) have inte

297 abdominal pain and diarrhea in patients with irritable bowel syndrome with diarrhea (IBS-D) without c

298 Chronic idiopathic constipation (CC) and irritable bowel syndrome with predominant constipation (

299 ctional bowel disorders (FBDs), particularly irritable bowel syndrome, with the objective of elucidat

300 abdominal pain experienced by patients with irritable bowel syndrome, yet the molecules that confer